Stelerix Web Blog Knowledge at your Fingertips

15Feb/110

KOL Engagement and Alignment.

Here's a quick excerpt from our Special Comprehensive Country Report, India. It's something we've seen addressed again and again in our follow-up interviews.  I've also thrown in a YouTube interview with Tushar Barad who talks about some of the intricacies of engaging with KOLs.

The updated report will be exclusively available for free through our great friends over at pharmaphorum. So you better get registered!

"Respondents identified active engagement of local Key Opinion Leaders as the most effective means to understand their needs. Further, this strategy provides accurate insight into actual affordability as demonstrated by purchasing power and cost of living, in addition to possible commercial strategies and their respective likelihoods. However, our research also suggested that organizations as a whole have been slow to actively engage end-users. Patience and value on the long term was also a key trend among respondents. It was evident from our results that success in India favors ongoing and long-term relationships that grow and evolve over time. While short-term profit can be made, it is clear that the initial time investment and requisite patience were rewarded many times over when focus was placed on the longer term.  A further benefit of continuous investment in “relationship capital” is the evolution of mutually business partnerships. Organizations who establish themselves effectively in India can often leverage their presence to reach other fast-growing markets in the South-Asian and Asia-Pacific region. Our experts agree that to be effective into 2020 and beyond, market leaders must invest proactively in nascent relationships, given the propensity for longer cycle time in such business partnerships. Opportunity to cut costs and drive access will exist for those who look to partner and aid, rather than exploit."

Posted by Jeff

Oh yeah, the full report will also be available for download here, but this week only!!

10Feb/110

Feature: Swami Samarth Pharmatech

We've got another interview up! Check out our exclusive feature with the owner of Mumbai-based Swami Samarth Pharmatech, Nitin Parab. He talks about what's necessary for success in

We're also hosting the web version of Nitin's upcoming event "Gateway to Europe, for Medical Devices."

We are lucky to have the partners we do.

Posted by Jeff

Posted by Jeff

9Feb/110

Contract Manufacturing Directory

Our site is always growing. The architecture elves never seem to stop building. Their resolve is impressive, now that I think about it.

I would write more, but it's probably easier if you just check it out yourself.

It's a list, that will continue to grow no-doubt, of contract manufacturing organizations all over the world.

We have also included a tool so that you can add your own company, if it's not there yet.

We're working on many more things, including a CRO list, so stay tuned for more developments to the site, and more content additions.

Posted by Jeff

8Feb/110

Trends in Translational Research.

Gregory Weiss was kind enough to take a few moments out of his Saturday morning to fill me in on some of the ground-breaking research he is doing at his UCI lab.

This particular clip is about his upcoming keynote remark at the Cambridge Health Institute conference, Therapeutic Approaches to Cancer Therapeutics. I will have the whole interview up soon. But for now, enjoy this!

Posted by Jeff

4Feb/110

Input in Action.

Thank you for the ongoing feedback. We are always growing, learning, and evolving. We appreciate hearing about how you think we might be able to do things a little bit better.

Today's update is regarding the library section of the main site. We've organized it into particular portals, organized by specific verticals that are of focus and interest to us. This was a change mandated by end-user input. Thanks for making our site easier to navigate and more engaging. We will continue to listen and implement your suggestions.

Check it out!

We have more changes in the pipeline and will update you here, as it happens!

Posted by Jeff

31Jan/110

Looking Way Ahead.

I encourage you to check out this exclusive interview. It is available to watch free on-demand. There is also a written summary if you want to get the goods quickly. I am especially excited about this conversation. I really enjoyed speaking with Vivek Shukla. His thoughts on success are an encouragement for anyone interested in self-improvement.

Going forward, based on user-input and our own intuition, this is likely the format we are going to stick with. We have improved the audio quality, and made the interview accessible for free, on-demand. There is also a Youtube clip to provide a rapid glimpse at what the entire interview holds.

We really appreciate getting input and feedback from our active users. Thanks for engaging with us. We will continue to integrate your preferences.

Posted by Jeff

28Jan/110

Value-Added Generics

I appreciate your patience in bearing with me in the last few weeks. As you undoubtedly know, I've been busy populating the library section of the main site. I am making a lot of progress, and there is even more in the pipeline.

One of the challenges has been ensuring high-quality audio. Much to my initial dismay, the sound-quality suffered on the first few recordings. For enduring this, I am grateful. After much experimentation I have found a methodology for getting things online relatively quickly and at high-fidelity.

I'm also picking out parts that I thought were of particular value. Here's a clip from Atul Sharma, talking about the importance of innovation in value-added generics.

Posted by Jeff

26Jan/110

Distribution Hurdles.

I caught up with Tushar Barad, Owner of Applied Biosciences, based in Mumbai, to ask him about some of the challenges and successes in his role. I'm editing the interview into bite-size portions, for now. I will compile on a page in the main site, but wanted to publish these wise words as quickly as possible. Here is the first excerpt. I hope you enjoy, as always, please leave your comments.

Posted by Jeff

25Jan/110

Patient Retention and Recruitment

I was lucky enough to catch up with Melynda Geurts, Chief Operating Officer at D. Anderson & Company (DAC). As a leading service provider, the DAC team leverages clinical trial expertise, creative acumen and site management excellence to produce measurable results.

DAC is scheduled to be appearing at a couple of upcoming conferences, so I kept it brief and honed in on the critical things to remember, in terms of effective clinical outsourcing and patient recruitment strategies, like, why it's worth remembering in the first place.

21Jan/110

It’s Ongoing.

Thanks for sticking with us. The exciting growth, over the in the library, has come somewhat at the extent of this Blog. But fear not, loyal reader. Our gradual improvement is an ongoing thing. Think of us as a value investment, good valuation (free!) and which will yield dividends over time.

We have a lot of exciting things in the pipeline, including some changes under the hood. And it's only going to get better.

In addition to technological steps forward, we perpetually reexamine and refine our ability to consistently provide high quality on-demand knowledge solutions. Our competitive advantage is in leveraging proprietary processes and a network of hands-on leaders in an array of global markets, for cost-effective, premium knowledge deliverables. We are always narrowing in on our specifically targeted verticals. We continue to grow partnerships with niche and industry specific leading content producers and distributors. Meanwhile, our in-house marketing, production, and primary research efforts sustain our unique and cutting-edge outlook; we integrate robust and renowned thought content and our own proprietary yet comprehensive gauge of industry sentiment, to bring well-contrasted strategies into sight.

For success, stay with us. It has come in incremental steps. And will continue to do so. With a minor setback or two along the way, of course. But like the Dow Jones, circa March 2009 to now, it'll be mostly up.

Posted by Jeff

Page 1 of 41234